NANOBIOTIX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.45 EUR | +0.93% |
|
+3.81% | -17.92% |
| Apr. 25 | Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024 | |
| Apr. 24 | Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 185 | 475.1 | 254.5 | 126.2 | 256.8 | - | - |
| Enterprise Value (EV) 1 | 194.5 | 404.9 | 216.6 | 137.9 | 281.1 | 284.8 | 256.8 |
| P/E ratio | -3.52 x | -9.86 x | -5.41 x | -2.21 x | -6.84 x | -32.7 x | -5.45 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 72.8 x | 189 x | 96.1 x | 26.4 x | 13 x | 7.07 x | 65.8 x |
| EV / Revenue | 76.5 x | 161 x | 81.8 x | 28.9 x | 14.2 x | 7.84 x | 65.8 x |
| EV / EBITDA | -4.32 x | -11.7 x | -4.24 x | - | -6.51 x | -5.96 x | -6.62 x |
| EV / FCF | -4.6 x | -14.7 x | - | -3.71 x | -8.43 x | -6.9 x | - |
| FCF Yield | -21.7% | -6.82% | - | -27% | -11.9% | -14.5% | - |
| Price to Book | -97.3 x | - | - | - | -3.34 x | -2.53 x | - |
| Nbr of stocks (in thousands) | 22,347 | 34,427 | 34,811 | 34,850 | 47,111 | - | - |
| Reference price 2 | 8.280 | 13.80 | 7.310 | 3.620 | 5.450 | 5.450 | 5.450 |
| Announcement Date | 3/17/20 | 3/17/21 | 3/30/22 | 4/24/23 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.541 | 2.512 | 2.647 | 4.776 | 19.79 | 36.33 | 3.9 |
| EBITDA 1 | -45.01 | -34.67 | -51.02 | - | -43.2 | -47.78 | -38.8 |
| EBIT 1 | -46.78 | -36.43 | -52.58 | -46.7 | -39.48 | -44.06 | -40.6 |
| Operating Margin | -1,840.97% | -1,450.16% | -1,986.36% | -977.85% | -199.5% | -121.3% | -1,041.03% |
| Earnings before Tax (EBT) 1 | -50.91 | -33.58 | -47 | -57.03 | -52.75 | -64.23 | -48.1 |
| Net income 1 | -50.92 | -33.59 | -47 | -57.04 | -40.34 | -27.65 | -48.1 |
| Net margin | -2,003.74% | -1,337.18% | -1,775.71% | -1,194.33% | -203.88% | -76.11% | -1,233.33% |
| EPS 2 | -2.350 | -1.400 | -1.350 | -1.640 | -0.7967 | -0.1667 | -1.000 |
| Free Cash Flow 1 | -42.26 | -27.63 | - | -37.2 | -33.35 | -41.3 | - |
| FCF margin | -1,663.12% | -1,100.08% | - | -778.81% | -168.54% | -113.69% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 3/17/20 | 3/17/21 | 3/30/22 | 4/24/23 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 Q3 | 2021 Q4 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | 1.823 | 0.718 | 1.448 | 1.064 | 1.319 | - | - | 1.329 | 3.447 | 3.293 | 12.18 | 14.2 | 14.2 |
| EBITDA | - | - | - | - | - | - | - | - | - | -24.63 | -24.16 | - | - |
| EBIT 1 | -20.47 | -26.31 | -18.38 | -18.04 | -29.78 | -14.11 | -14.11 | -25.88 | -20.82 | -25.37 | -10.76 | - | - |
| Operating Margin | -1,122.71% | -3,664.62% | -1,269.61% | -1,695.86% | -2,257.62% | - | - | -1,947.1% | -604.15% | -770.42% | -88.28% | - | - |
| Earnings before Tax (EBT) 1 | -23.92 | -26.99 | -20.58 | -13 | -30.42 | -8.29 | -8.29 | -26.35 | -30.68 | -28.1 | -17.66 | - | - |
| Net income 1 | -23.92 | -27 | -20.58 | -13.01 | -30.42 | -8.29 | -8.29 | -26.36 | -30.68 | -28.1 | -23.64 | -18.2 | -19.2 |
| Net margin | -1,312.12% | -3,759.75% | -1,421.2% | -1,222.84% | -2,306.29% | - | - | -1,983.22% | -890.17% | -853.29% | -194.07% | -128.17% | -135.21% |
| EPS | -1.150 | -1.200 | -0.9100 | -0.4900 | -0.8800 | - | - | -0.7600 | - | -0.8000 | -0.3450 | -0.3900 | -0.3700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 9/4/19 | 3/17/20 | 9/4/20 | 3/17/21 | 9/8/21 | 4/8/22 | 3/30/22 | 9/28/22 | 4/24/23 | 9/26/23 | - | - | - |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | 9.43 | - | - | 11.8 | 24.4 | 28.1 | - |
| Net Cash position 1 | - | 70.2 | 37.9 | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.2095 x | - | - | - | -0.5636 x | -0.587 x | - |
| Free Cash Flow 1 | -42.3 | -27.6 | - | -37.2 | -33.4 | -41.3 | - |
| ROE (net income / shareholders' equity) | -826% | -98% | -96.7% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | -0.0900 | - | - | - | -1.630 | -2.150 | - |
| Cash Flow per Share 2 | -1.900 | -1.130 | -0.8600 | - | -0.7100 | -0.6600 | - |
| Capex 1 | 1.09 | 0.1 | 0.23 | 0.09 | 0.97 | 0.54 | 0.2 |
| Capex / Sales | 42.94% | 3.82% | 8.61% | 1.93% | 4.92% | 1.49% | 5.13% |
| Announcement Date | 3/17/20 | 3/17/21 | 3/30/22 | 4/24/23 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.45
EUR
Average target price
11.3
EUR
Spread / Average Target
+107.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.92% | 274M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- NANO Stock
- Financials Nanobiotix
